-
Document de presse | 2020.04.30
Revealing how SARS-CoV-2 hijacks human cells; points to drugs with potential to fight COVID-19 and a drug that aids its infectious growth
An international effort including researchers from University of California San Francisco (UCSF), Gladstone Institutes, Icahn School of Medicine at Mount Sinai and Institut Pasteur (Paris) unveils promising compounds for clinical testing against COVID-19. The study, led by UCSF Quantitative Biosciences Institute Director, Nevan Krogan, PhD, reveals that some drugs may fight COVID-19...
-
Document de presse | 2020.05.07
Achilles’ heel for reseeding of the viral reservoir after stem cell transplantation in people with HIV
Current HIV treatments efficiently block viral multiplication but cannot cure infection as they do not target HIV infected cells. HIV cure or profound HIV remission have been described in three persons with HIV who underwent allogeneic stem cell transplantation to treat severe blood cancers. However, this procedure has not eradicated the virus in other persons. A work led by scientists from the...
-
Page avancée | 2020.05.12
Pasteur workshops
-
News | 2020.05.14
LuLISA project, bioluminescence as a tool for human diagnostics, from allergy to Covid19
The LuLISA (Luciferase-Linked ImmunoSorbent Assay) research project aims developing high throughput serological tests for epidemiological studies at local, regional or nation scales. In a recent scientific publication, concerning the detection and dosing of IgE specific to several allergens in patients’ blood samples, the use of LuLISA proves to be a vastly improved detection method in...
-
News | 2020.07.27
A new biotechnology tool to tackle antibiotic resistance
Designing effective new molecules to tackle infectious diseases is a difficult process that currently represents a huge challenge for scientists, especially given the rise in bacterial resistance to antibiotics. Scientists from the Institut Pasteur's Bacterial Genome Plasticity Unit have responded to this challenge by developing a new biotechnological tool which bypasses the sampling limitations...
-
News | 2020.05.20
Blood test: a potential new tool for controlling infections
A new technique could provide vital information about a community’s immunity to infectious diseases including malaria and Covid-19.The diagnostic test analyses a blood sample to reveal immune markers that indicate whether – and when – a person was exposed to an infection. It was developed to track malaria infections in communities, to assist in the elimination of deadly ‘relapsing’ malaria, but...
-
Document de presse | 2020.05.26
MV-SARS-CoV-2 vaccine candidate: a new partnership between Institut Pasteur, CEPI, Thémis and MSD
Institut Pasteur announces recent advances in the development of one of its candidate vaccines, MV-SARS-CoV-2, using the measles vector, as part of a renewed partnership with CEPI and the companies Thémis and MSD.With over 100 vaccine projects in development worldwide, the development of a vaccine against SARS CoV-2 infection remains a challenge, with many scientific uncertainties ahead. The...
-
Page avancée | 2020.05.26
2019 Theses and Ceremony
2019 Theses and Ceremony
-
News | 2020.05.26
Tiger mosquito in France: 58 départements on red alert
In early May 2020, the French health authorities placed 58 of the country's départements on "red alert" in their map showing the spread of the tiger mosquito in France – seven more than in 2019. The Aedes albopictus mosquito, originally from Asia, has been present in France since 2004. It is the vector for diseases such as dengue, chikungunya and Zika.The tiger mosquito (...
-
Document de presse | 2020.05.26
COVID-19: the vast majority of patients with a minor form develop neutralizing antibodies
Teams from Strasbourg University Hospital and the Institut Pasteur carried out a study among hospital staff on the two sites of Strasbourg University Hospital. After observing 160 people with minor forms of COVID-19, the scientists concluded that nearly all the patients developed antibodies within two weeks of being infected. In 98% of the patients, neutralizing antibodies were detected after 28...
